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Background: Cardiomyocytes apoptosis is an important contributor to myocardial dysfunction and heart failure.
Adiponectin has cardioprotective effects, potential mechanisms behind it are not clear in cardiomyocytes. The
purpose of the study was to investigate whether adiponectin can block palmitate-induced apoptosis and the
underlying biochemical mechanism in H9c2 cells.
Methods: H9c2 cells were treated with palmitate presence or absence of 2.5 μg/mL globular adiponectin. The
effect on the cell viability of H9c2 cells was evaluated using MTT assay, and cell apoptosis was determined by
Hoechst 33342 staining. Protein expression was measured using the western blot method.
Results: Our results showed that the palmitate treatment induced apoptosis in H9c2 cells, which was associated
with increasing the level of cleaved caspase-3 and cleaved PARP. Meanwhile, palmitate-induced apoptosis increased
the protein level of p-ERK1/2, and decreased the protein level of p-Akt significantly. However, levels of both of
these proteins were restored to the normal when pretreated with adiponectin, and followed with the decrease of
cleaved caspase-3 and cleaved PARP. In line with these results, the protective effect of adiponectin can be blocked
by PI3K/Akt inhibitor LY294002, and palmitate-induced apoptosis can be attenuated by ERK1/2 inhibitor U0126.
Conclusions: Taken together, the present study demonstrated that adiponectin protects H9c2 cells from
palmitate-induced apoptosis via PI3K/Akt and ERK1/2 signaling pathways. Our results reveal a link between
adiponectin and cardiomyocytes apoptosis, suggesting that adioponectin may be a promising therapeutic for the
treatment of lipotoxicity cardiomyopathy.
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Lipids over accumulation in the heart are associated
with cardiac dysfunction and heart failure [1,2]. Satu-
rated fatty acid such as palmitate (C16:0) but not mono-
unsaturated oleate (C18:1) induced apoptosis in many
cell types including the cardiomyocytes element of the
heart [3]. Several studies showed that high levels of
palmitate had caused significant increases of ceramide
and mitochondrial cytochrome c release levels, which
was accompanied by significant caspase-3 activation and* Correspondence: yanlitf@yahoo.com.cn
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reproduction in any medium, provided the orapoptosis [4,5], and this lipotoxicity effect on cardiac
myocytes apoptosis remains incompletely understood.
Cardiomyocytes apoptosis is an important contributor to
myocardial dysfunction and heart failure, and blockade
of myocardial apoptosis results in significant prevention
of diabetes-induced cardiac dysfunction [6].
Adiponectin is an adipokine secreted from adipose
tissue and plasma with concentrations ranging from 3
to 30 μg/mL in mouse and human [7,8]. The structure
of adiponectin contains a collagen-repeat domain at
the N-terminus and a globular domain at the C-terminus
with a sequence homology to compliment factor C1q [8].
The C-terminal globular C1q domain of adiponectin is
proteolytically cleaved from the full length protein and is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mediate potent physiological effects [9,10]. Recently, a
number of studies have shown that adiponectin tran-
scripts are synthesized by cardiomyocytes [11], which are
upregulated in mouse models of myocardial injury [12,13].
To date, adiponectin has been extensively documented to
mediate several cardioprotective properties [14], and anti-
apoptotic effect of adiponectin on the heart [12,13,15].
Phosphatidylinositol 3-kinase (PI3K)/Akt and extracellu-
lar signaling regulated kinase (ERK1/2)/mitogen-activated
protein kinase (MAPK) signaling pathways are an import-
ant for intracellular signal transduction system. PI3K/Akt
has been shown to play a major role in the prevention of
apoptosis [16], and ERK1/2 is a well-known taking part in
a signal transduction cascade in response to extracellular
stimuli, and plays an important role in cell proliferation,
growth and cell death [17]. Several studies have exhibited
that anti-apoptotic effect of adiponectin on the heart,
which appeared to be mediated via PI3K/Akt, ERK1/
2MAPK and AMP-activated protein kinase (AMPK) sig-
naling pathway [15,18,19]. Adiponectin could protect
against acute cardiac injury by attenuating the apoptosis,
but the mechanism involved the effect of adiponectin in
palmitate-induced apoptosis are not fully understood.
In the present study, we demonstrated that adiponectin
protected H9c2 cells from palmitate-induced apoptosis
through both PI3K/Akt and ERK1/2 signaling pathways.
Materials and methods
Chemicals and reagents
Dulbecco’s Modified Eagle Medium (DMEM) and Peni-
cillin/Streptomycin were obtained from Thermo Scien-
tific Hyclone (Hyclone, US). Rat recombinant globular
adiponectin (gAd) was purchased from Biovision (Biov,
USA). Antibodies for the phosphorylated Akt at Ser473,
total-Akt, cleaved caspase-3, poly (ADP-ribose) poly-
merase (PARP), inhibitor of PI3K LY29002, inhibitor of
p-ERK1/2 U0126, HRP-conjugated anti-rabbit or anti
mouse secondary antibodies were obtained from Cell
Signaling Technology (Cell signaling, USA). Antibodies
for the phosphorylated at Thr202/Tyr204 extracellular-
regulated kinase (p-ERK1/2), total ERK1/2, β-actin,
and Enhanced chemiluminescence (ECL) reagent were
purchased from Millipore (Millipore, USA). Palmitate
(PA) and Bovine Serum Albumin (BSA) were obtained
from Sigma Aldrich (Sigma, USA). The stock solutions
5 mM PA/10% BSA that can be stored at −20°C was
prepared reference from [20]. The 5 mM PA/10% BSA
stock solutions are heated for 15 min at 55°C, and then
cooled to room temperature before use.
Cell culture
H9c2 cells (a subclone of the original clonal cell line
derived from embryonic BD1X rat heart tissue exhibitingmany of the properties of skeletal muscle) obtained from
Chinese Collection of Cell Cultures, were grown in Dul-
becco’s Modified Eagle’s Medium (DMEM) supplemen-
ted with 10% fetal bovine serum and 1% penicillin–
streptomycin in a humidified atmosphere of 95% air-5%
CO2 at 37°C. In addition, the various treatments for cells
were carried out only when cells reach about 80% of
confluence in appropriate culture dish.
Nuclear staining with Hoechst 33342
Cell were plated in 6 well chamber slides and allowed to
adhere. Following 12 h different treatment, cells from
each group were washed with phosphate buffered saline
and fixed with 4% formalin for 10 min. Hoechst 33342
(10 μg/mL) was applied for 30 min under dark condition
to stain the nuclei of fixed cells. Slides were then washed
with phosphate buffered saline and mounted in a mount-
ing medium (phosphate buffered saline: glycerol, 1:1), and
observed under a fluorescence microscope. Apoptotic
cells were identified as those with a nucleus exhibiting
brightly stained condensed chromatin or unclear frag-
ments. For each experimental condition, four separate cell
populations were prepared. Apoptotic indices were deter-
mined by direct visualization and counting of a minimum
of 500 cells per population (at least 100 cells from five
randomly selected fields). The apoptotic index was calcu-
lated as the ratio of number of apoptotic cells to total cells
counted × 100.
Cell viability assay
Cell viability was measured using the MTT (3-(4,5)-
dimethylthiahiazo (−z-y1)-3,5-diphenytetrazoliumromid)
assay, based on the MTT conversion into formazan crys-
tals using mitochondrial dehydrogenases. Briefly, H9c2
cells were plated at a density of 1 × 104 cells/well in 96-well
plates. After different treatment for 12 h, the culture
medium was replaced with 200 μL MTT solution (5 mg/mL
stock solution in PBS, diluted with culture medium to the
final concentration 0.5 mg/mL). After 4 h incubation
at 37°C, this solution was removed and the produced
formazan was solubilized in 150 μL dimethyl sulfoxide
(DMSO). The absorbance was measured at 550 nm
using an automated microplate reader.
Immunoblot
Cells were lysed in ice-cold RIPA buffer (50 μM Tris/
HCl, pH 7.4, 150 μM NaCl, 1% NP-40, 0.5% Deoxycho-
late, 0.1% Sodium dodecyl sulfate) and the protease of
inhibitor phenylmethanesulfonyl fluoride (PMSF). Protein
concentration of the cell samples was determined using
the bicinchoninic acid protein assay reagent kit (Pierce
Biotechnology, USA) with bovine serum albumin as
standard. For Western blot analysis, 40 μg of protein was
denatured by heating 100°C for 10 min in SDS sample
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polyacrylamide gels, and then transferred electrically to a
polyvinylidene fluoride (PVDF) membrane. The mem-
brane was blocked in 5% (wt/vol) nonfat milk with 0.05%
Tween-20 TBS buffer for 1 h and then was incubated
overnight with the following different primary antibodies:
monoclonal anti-Akt (1:1000) and anti-p-Akt (ser473)
(1:1000), monoclonal anti-cleave caspase-3 (1:500), mono-
clonal anti-PARP (1:1000), monoclonal anti-p-ERK1/2
(Thr202/Tyr204) (1:500), monoclonal anti-ERK1/2 (1:500),
and anti-β-actin antibody (1:2000) was used to show equal
loading of the protein in the western blotting and quantita-
tive analysis. The membranes were incubated with
horseradish peroxidase-linked anti-mouse or anti-rabbit
secondary antibody at 1:3000 dilutions for 1 h at 37°C
and, after washes, visualized for immunoreactivity using
an Enhanced Chemiluminescence (ECL) System.
Statistical analysis
Quantitative data are presented as the means ± SE deter-
mined from at least three independent of experiments.
Statistical analysis was based on Student’s t test for com-
parison of two groups or one-way ANOVA for multiple
comparisons. P value <0.05 was considered significant.
Results
Palmitate-induced H9c2 cells apoptosis through
activation of caspase-3 and PARP
In order to determine the toxic effects of palmitate on
H9c2 cells, cells were treated with increasing palmitate
(PA) from 0 to 250 μM for 12 h. An increase in the
number of apoptotic cells was observed in H9c2 cells by
Hoechst 33342 staining (Figure 1A, B), and decreased
cell viability was measured by a MTT assay (Figure 1C).
Next, we choose the 150 μM palmitate in subsequent
experiments to analyze cleaved caspase-3 and the cleav-
age of poly (ADP-ribose) polymerase (PARP), two well-
established hallmarks of apoptosis [21,22]. Immunoblot
and quantitative analysis results showed that expression
of cleaved caspase-3 was detected at 2 h after treatment
with 150 μM palmitate, and increased gradually at 6 h,
12 h and 24 h (Figure 1D). The analysis result of PARP
cleavage (Figure 1E) was similar to that of the cleaved
caspase-3. These results suggested that caspase-3 and
PARP activation were involved in the apoptotic pathway
induced by palmitate in H9c2 cells.
Adiponectin attenuated palmitate-induced H9c2 cells
apoptosis through reduced the activation of caspase-3
and PARP
Adiponectin exists in the circulation as a full-length pro-
tein and cleaved globular C-terminal domain, both of
which are pharmacologically active [9]. In this study,
there were three groups, 1% BSA control, palmitate(PA) treated group as well as globular adiponectin
(gAd) and palmitate treated group, and the concentra-
tion of 2.5 μg/mL globular adiponectin was chosen refer-
ence from [23]. Cells were treated with 150 μM palmitate
for 12 h or pretreated with 2.5 μg/mL globular adiponectin
for 1 h and then treated with 150 μM palmitate for 12 h.
BSA treated cells were used as the control. After the treat-
ment, apoptosis of cell was measured using Hoechst
33342 staining, viability of cells was measured by a MTT
assay; and expression of cleaved caspase-3 and cleaved
PARP were measured by immunoblot. Results showed that
apoptosis of cells increased (Figure 2A, B), viability of cells
reduced (Figure 2C), levels of cleaved caspase-3 and
cleaved PARP increased significantly after treated with
palmitate (Figure 2D, E). However, when pretreated with
adiponectin, we found that adiponectin pretreatment sig-
nificantly decreased apoptosis of cells (Figure 2A, B),
increased viability of cells (Figure 2C), reduced the level of
cleaved caspase-3 (Figure 2D) as well as cleaved PARP
(Figure 2E). These results indicated that adiponectin
might attenuate palmitate-induced apoptosis in H9c2 cells
through reducing the activation of caspase-3 and PARP.
PI3K/Akt was involved in the process of adiponectin-
mediated anti-apoptosis
Adiponectin is also known to activate PI3K/Akt signaling
pathway, and the involvement of this signaling pathway in
suppressive effects of adiponectin on palmitate-induced
apoptosis was investigated by PI3K inhibitor, LY294002.
The level of p-Akt was decreased after exposure of H9c2
cells to palmitate for 12 h (Figure 3A). Simultaneously the
level of cleaved caspase-3 and cleaved PARP was increased
significantly (Figures 2C, D). Cells were first pretreated
with 2.5 μg/mL globular adiponectin, then treated with
palmitate for 12 h, and lastly assayed by immunoblot.
Results showed that the level of p-Akt decreased dra-
matically after treated with palmitate. However, its
level restored to the control level after pretreated with
2.5 μg/mL globular adiponectin (Figure 3A). To test
whether PI3K/Akt signaling pathway was involved in
the inhibitory effect of adiponectin on palmitate-
induced apoptosis in H9c2 cells, we used the inhibitor of
PI3K/Akt, 10 μM LY294002 reference from [24]. Cells
were first pretreated with 10 μM LY294002 for 1 h, then
treated with 2.5 μg/mL globular adiponectin for another
1 h, and lastly treated with palmitate for 12 h. Results showed
that the restored level of p-Akt induced by 2.5 μg/mL globular
adiponectin was decreased again (Figure 3B), and levels of
cleaved caspase-3 and cleaved PARP were also reversed after
pretreated with LY294002 compared with 2.5 μg/mL globular
adiponectin plus palmitate group (Figure 3C, D). Taken to-
gether, these results demonstrated that adiponectin partially
inhibited palmitate-induced apoptosis in H9c2 cells via activat-
ing the PI3K/Akt signaling pathway.
Figure 1 Palmitate-induced H9c2 cells apoptosis. Cells were treated with different concentrations of palmitate (0 μM, 100 μM, 150 μM and
250 μM) for 12 h, cell apoptosis was determined by Hoechst 33342 staining (A and B), and cell viability was measured using MTT assay (C). Cells
were treated with 150 μM palmitate on time-dependent. Levels of cleaved caspase-3 (D) and PARP (E) were measured by immunoblot and
quantitative analysis. These results were reported as mean ± S.E.M. * P< 0.05 versus control.
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adiponectin-mediated anti-apoptosis
In the present study, results showed that the level of
p-ERK1/2 increased significantly when treated with
palmitate for 12 h (Figure 4A) whereas the level of p-ERK1/
2 decreased significantly and almost restored to the normal
by pre-incubation with 2.5 μg/mL globular adiponectin.
Taken together, these results suggested that adiponectin sup-
pressed palmitate-induced apoptosis (Figure 2C, D) through
reducing the activity of ERK1/2 signaling pathway. In order
to further determine the role of the ERK1/2 in palmitate-
induced H9c2 cells apoptosis, we used its inhibitor, 10 μM
U0126 reference from [25]. We found that the level of
p-ERK1/2 decreased significantly when treated with 10 μMU0126 in the presence of palmitate (Figure 4B) and the
level of cleaved caspase-3 and cleaved PARP also
decreased (Figures 4C, D). The results demonstrated that
ERK1/2 signaling pathway was involved in palmitate-
induced apoptosis in H9c2 cells and adiponectin partially
inhibited palmitate-induced apoptosis through decreasing
the level of phosphorylated ERK1/2.
PI3K/Akt and ERK1/2 signaling pathway crosstalk plays a
role in regulating adiponectin attenuated palmitate-
induced apoptosis in H9c2 cells
Previous results indicated that 2.5 μg/mL globular adi-
ponectin can attenuate palmitate-induced apoptosis in
H9c2 cells through decreasing the level of p-ERK1/2,
Figure 2 Effects of adiponectin on palmitate-induced apoptosis in H9c2 cells. Cells were pretreated with 2.5 μg/mL globular adiponectin
for 1 h before exposure to 150 μM palmitate for 12 h. Cell apoptosis was determined by Hoechst 33342 staining (A and B), and cell viability was
measured using MTT assay (C). Levels of cleaved caspase-3 (D) and PARP (E) were measured by immunoblot and quantitative analysis. Results
were reported as mean ± S.E.M. * P< 0.05 versus control, # P< 0.05 versus PA.
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esting question was whether partial recovery of the activity
of PI3K/Akt signaling pathway could lead to a decreased
activity of ERK1/2 signaling pathway. Therefore, we fur-
ther investigated the relationship between ERK1/2 and
PI3K/Akt signaling pathway in adiponectin-mediated anti-
apoptosis in H9c2 cells. Cells were exposed to 2.5 μg/mL
globular adiponectin plus palmitate in the absence or the
presence of PI3K inhibitor, 10 μM LY294002. Datashowed that the level of p-ERK1/2 was increased dramat-
ically (Figure 5A). Meanwhile, the level of p-Akt was also
increased after cells were exposed to palmitate combined
with ERK1/2 inhibitor 10 μM U0126 (Figure 5B). These
results indicated that partial inhibition of PI3K/Akt signal-
ing pathway resulted in activation of ERK1/2 signaling
pathway, which attenuated effects of globular adiponectin
on anti-apoptosis; and partial inhibition of ERK1/2 signal-
ing pathway resulted in activation of PI3K/Akt signaling
Figure 3 PI3K/Akt signaling pathway was involved in the process of adiponectin’s anti-apoptosis in H9c2 cells. Cells were pretreated
with 2.5 μg/mL globular adiponectin for 1 h, in the presence or absence of PI3K inhibitor, LY294002, and then exposure to 150 μM palmitate for
12 h. Levels of p-Akt (A and B), t-Akt (A and B), cleaved caspase-3 (C) and PARP (D) were measured by immunoblot and quantitative analysis.
These results were reported as mean ± S.E.M. * P< 0.05 versus control, # P< 0.05 versus PA and ※ P< 0.05 versus (PA + gAd).
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in H9c2 cells.
Discussion
Free fatty acids, such as saturated fatty acids are now
recognized as significant contributors to lipotoxicity
pathology including insulin resistance, type 2 diabetes,
and cardiomyopathy [26]. Palmitate as a kind of satu-
rated fatty acids can induce apoptosis in diverse cell
types, such as cardiomyocytes [27]. Apoptosis or pro-
grammed cell death is basically cellular suicide which
occurs after sufficient cellular damage. Caspase-3, a mem-
ber of cysteine-aspartic proteases that play a central role
in the execution of the apoptotic program, exists as an in-
active 32-kDa proenzyme in normally. The cleavage
within the 19-kDa fragment generates a p17-kDa subunit(termed p17) as an activity form. During apoptosis,
caspase-3 cleaved the 116-kDa PARP protein to yield a
24-kDa DNA-binding fragment and an 89-kDa catalytic
fragment [28]. In this study, our results showed that
palmitate-induced apoptosis through increasing the activ-
ity of caspase-3 and PARP in H9c2 cells.
Adiponectin, an abundant circulating adipokine, is al-
most exclusively secreted from adipose tissue and exists
in the range of 3–30 μg/mL in plasma. Although its
physiological and pathological significance remains to be
determined, numerous epidemiological studies have
shown that the correlation between reduced adiponectin
levels and increased morbidity/mortality of cardiovascular
ischemic diseases and diabetes mellitus [29,30]. Con-
versely, a higher plasma adiponectin concentration is asso-
ciated with a lower risk of ischemic heart disease [31].
Figure 4 ERK1/2 signaling pathway was also involved in the process of adiponectin’s anti-apoptosis in H9c2 cells. Cells first were
pretreated with 2.5 μg/mL globular adiponectin for 1 h, in the presence or absence of ERK1/2 inhibitor, U0126 (10 μM), and then exposed to 150
μM palmitate for 12 h. Levels of p-ERK1/2 (A and B), total-ERK1/2 (A and B), cleaved caspase-3 (C) and PARP (D) were measured by immunoblot
and quantitative analysis. Results were reported as mean ± S.E.M. * P< 0.05 versus control, # P< 0.05 versus PA.
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myocardial dysfunction and heart failure, so preventing
cardiomyoytes apoptosis is an effective way to protect
myocardial function. Recently some published in vivo
studies demonstrated that adiponectin functioned as
a cardioprotective molecule in myocardial ischemia-
reperfusion injury [12,18,32]. The results of these research
exhibited that exogenous adiponectin supplementation
can significantly decrease myocardial apoptosis, infarct
size and impaired cardiac function. More detailed in vitro
studies regarding anti-apoptotic mechanisms of adiponec-
tin have been performed in different cell types [33-35].
Although adiponectin also inhibited hypoxia/reoxygena-
tion (H/R)-induced apoptosis through reducing cyto-
chrome c release and decreasing the activity of caspase-3in H9c2 cells [10], it is not clear that there is the effect of
adiponectin on palmitate-induced apoptosis in H9c2 cells.
In this study, our results showed that globular adiponec-
tin inhibited palmitate-induced apoptosis in H9c2 cells
through decreasing the activity of caspase-3 and PARP.
Above data indicated that adiponectin might be a novel
therapeutic molecule for anti-apoptosis in cardiomyo-
pathy and myocardial damage.
Recently many studies showed that several signaling
transduction pathways were shown to mediate both of
pro- and anti-apoptosis effects in numerous tissues and
cell types by adiponectin, such as (PI3K)/Akt signaling
pathway, MAPK/ERK and AMPK.
Notably, PI3K/Akt signaling pathway has been shown
to play a major role in the prevention of apoptosis [16],
Figure 5 Crosstalk between PI3K/Akt and ERK1/2 signaling pathway of palmitate-induced apoptosis in H9c2 cells. Cells were pretreated
with LY294002 (10 μM) or U0126 (10 μM) for 1 h, and then treated with 2.5 μg/mL globular adiponectin for 1 h before exposure to 150 μM
palmitate for 12 h. Levels of p-ERK1/2 and t-ERK1/2 (A), p-Akt and t-Akt (B) were measured by immunoblot and quantitative analysis. These results
were reported as mean ± S.E.M., * P< 0.05 versus control, # P< 0.05 verus PA and ※ P< 0.05 versus (PA + gAd).
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both cardiomyocyte survival and function in vitro and
in vivo [36]. Previous studies have shown that adiponec-
tin can activate the Akt signaling pathway to promote
pro-survival or anti-apoptosis in several cell types
[35,37,38]. Here, our results showed that globular adipo-
nectin can attenuate apoptosis induced by palmitate in
H9c2 cells through decreasing the activity of caspase-3
and PARP. This effect was abolished by LY294002, a
highly specific inhibitor of PI3K/Akt. This data sug-
gested that activation of PI3K/Akt signaling pathway
was necessary for adiponectin mediated inhibition of
H9c2 cells apoptosis induced by palmitate.
ERK1/2/MAPK is a well-known taking part in a signal
transduction cascade in response to extracellular stimuli,
and plays an important role in cell proliferation, growth
and cell death [17]. Research indicated that ERK1/2
signaling pathway would be activate by doxorubicin-
induced apoptosis in H9c2 cells [39]. Adiponectin
mediates activation of the ERK1/2 signaling pathway in
several cell types [19,40]. Nevertheless, suppression of
the activity of ERK1/2 signaling pathway by adiponectin
has also been demonstrated [41]. Therefore, it seems
that the effect of adiponectin on ERK1/2 signaling path-
way is controversial. In this study, our results showed
that the p-ERK1/2 was increased after palmitate-induced
apoptosis in H9c2 cells, and globular adiponectin
decreased the level of p-ERK1/2, and then inhibitedpalmitate-induced apoptosis in H9c2 cells through
decreasing the activity of caspase-3 and PARP. In our
results also showed that the level of p-ERK1/2 was
increased after palmitate-induced apoptosis in H9c2
cells, and ERK1/2 inhibitor U0126 can decrease the level
of p-ERK1/2, and then attenuate palmitate-induced
apoptosis in H9c2 cells. These results suggest that acti-
vation of ERK1/2 signaling pathway may be one of the
reasons for palmitate-induced apoptosis in H9c2 cells.
Our findings in this study showed that PI3K/Akt in-
hibitor LY294002, not only inhibited the activity of
PI3K/Akt signaling pathway, blocked adiponectin’s in-
hibition of palmitate-induced apoptosis in H9c2 cells,
but also increased the activity of ERK1/2 signaling path-
way. Similarly, ERK1/2 inhibitor U0126 also reduced
palmitate-induced apoptosis in H9c2 cells, increased the
activity of PI3K/Akt signaling pathway and thus pro-
moted cells survival. This crosstalk of ERK1/2 and PI3K/
Akt were observed in other study [42]. These results
suggested that ERK1/2 and PI3K/Akt signaling pathways
maybe crosstalk regulates survival and apoptosis in
H9c2 cells after treated with palmitate, but it regulates
mechanism crosstalk in H9c2 cells require further
investigation.
Conclusions
Taken together, these results demonstrated that globular
adiponectin can inhibit palmitate-induced apoptosis in
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PARP and inhibiting the activation of the ERK1/2 signaling
pathway while activating of the Akt signaling pathway. This
study not only enriched mechanisms of adiponectin-
mediated anti-apoptosis in cardiomyocytes, but also pro-
vided valuable evidence for identifying adioponectin as a
candidate for the treatment of lipotoxicity cardiomyopathy.
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